[8-K] Y-mAbs Therapeutics, Inc. Reports Material Event
Y-mAbs Therapeutics reported that it has announced its financial results for the quarter ended June 30, 2025 and furnished a related press release as Exhibit 99.1 to this Form 8-K. The filing states that the material furnished, including Exhibit 99.1, is not to be deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except by specific reference.
The text of this 8-K does not include any financial metrics or operating results; an Interactive Data File (Inline XBRL) is included as Exhibit 104. Investors must review the attached press release for the actual financial details.
Y-mAbs Therapeutics ha comunicato di aver reso noti i risultati finanziari per il trimestre terminato il 30 giugno 2025 e ha allegato il comunicato stampa come Exhibit 99.1 a questo Form 8-K. Il deposito precisa che il materiale fornito, incluso l'Exhibit 99.1, non deve essere considerato "filed" ai fini della Section 18 of the Exchange Act e non 猫 incorporato per riferimento in altre dichiarazioni, salvo esplicito riferimento.
Il testo di questo 8-K non contiene metriche finanziarie n茅 risultati operativi; un Interactive Data File (Inline XBRL) 猫 incluso come Exhibit 104. Gli investitori devono consultare il comunicato stampa allegato per i dettagli finanziari completi.
Y-mAbs Therapeutics inform贸 que ha anunciado sus resultados financieros del trimestre terminado el 30 de junio de 2025 y ha presentado el comunicado de prensa como Exhibit 99.1 en este Form 8-K. El documento indica que el material suministrado, incluido el Exhibit 99.1, no debe considerarse "filed" a efectos de la Section 18 of the Exchange Act y no se incorpora por referencia en otros formularios salvo que se haga referencia expl铆cita.
El texto de este 8-K no incluye m茅tricas financieras ni resultados operativos; un Interactive Data File (Inline XBRL) figura como Exhibit 104. Los inversores deben revisar el comunicado de prensa adjunto para conocer los detalles financieros.
Y-mAbs Therapeutics電� 2025雲� 6鞗� 30鞚�搿� 雭濍倶電� 攵勱赴鞚� 鞛鞁れ爜鞚� 氚滍憸頄堨溂氅�, 甏�霠� 氤措弰鞛愲毳� 鞚� Form 8-K鞚� Exhibit 99.1搿� 鞝滌稖頄堧嫟瓿� 氚濏様鞀惦媹雼�. 鞝滌稖靹滊電� 鞝滉车霅� 鞛愲(頃措嫻 Exhibit 99.1 韽暔)臧赌 Section 18 of the Exchange Act鞚� 氇╈爜靸� "filed"搿� 臧勳＜霅橃 鞎婌溂氅�, 氇呾嫓鞝� 彀胳“臧� 鞛堧姅 瓴届毎毳� 鞝滌櫢頃橁碃 雼るジ 鞝滌稖靹滊鞐� 彀胳“搿� 韽暔霅橃 鞎婋姅雼り碃 氇呾嫓頃╇媹雼�.
鞚� 8-K鞚� 氤鸽鞐愲姅 鞛 歆�響滊倶 鞓侅梾鞁れ爜鞚� 韽暔霅橃柎 鞛堨 鞎婌溂氅�, Interactive Data File (Inline XBRL)鞚� Exhibit 104搿� 觳秬霅橃柎 鞛堨姷雼堧嫟. 鞁れ牅 鞛 靹鸽秬靷暛鞚� 觳秬霅� 氤措弰鞛愲毳� 頇曥澑頃挫暭 頃╇媹雼�.
Y-mAbs Therapeutics a annonc茅 avoir publi茅 ses r茅sultats financiers pour le trimestre clos le 30 juin 2025 et avoir communiqu茅 le communiqu茅 de presse correspondant en tant que Exhibit 99.1 de ce Form 8-K. Le d茅p么t pr茅cise que les documents fournis, y compris l'Exhibit 99.1, ne doivent pas 锚tre consid茅r茅s comme "filed" aux fins de la Section 18 of the Exchange Act et ne sont pas incorpor茅s par r茅f茅rence dans d'autres d茅p么ts sauf mention expresse.
Le texte de ce 8-K ne contient aucune donn茅e financi猫re ni r茅sultat op茅rationnel ; un Interactive Data File (Inline XBRL) est joint en tant que Exhibit 104. Les investisseurs doivent consulter le communiqu茅 de presse ci-joint pour obtenir les d茅tails financiers.
Y-mAbs Therapeutics teilte mit, dass das Unternehmen seine Finanzergebnisse f眉r das Quartal zum 30. Juni 2025 bekanntgegeben und die zugeh枚rige Pressemitteilung als Exhibit 99.1 zu diesem Form 8-K eingereicht hat. Die Einreichung weist darauf hin, dass das bereitgestellte Material, einschlie脽lich des Exhibit 99.1, im Sinne von Section 18 of the Exchange Act nicht als "filed" gilt und nicht durch Verweis in andere Unterlagen aufgenommen wird, es sei denn, dies geschieht ausdr眉cklich.
Der Text dieses 8-K enth盲lt keine finanziellen Kennzahlen oder Betriebsergebnisse; eine Interactive Data File (Inline XBRL) ist als Exhibit 104 beigef眉gt. Anleger m眉ssen die beigef眉gte Pressemitteilung einsehen, um die konkreten Finanzangaben zu erhalten.
- Disclosure of quarterly results for the period ended June 30, 2025
- Press release attached as Exhibit 99.1 and Interactive Data File included as Exhibit 104
- No financial figures, metrics, or explanations are contained in the 8-K text
- Information is explicitly "furnished" not "filed", limiting incorporation and Section 18 liability
Insights
TL;DR: Routine earnings disclosure furnished without in-text financial figures; impact depends on the attached press release.
The Form 8-K notifies the market that Y-mAbs has announced results for the quarter ended June 30, 2025 and attaches the announcement as Exhibit 99.1. Because the filing itself contains no revenue, EPS, cash, or guidance figures, the 8-K alone provides limited information for valuation or short-term trading decisions. The filing also clarifies the press release is "furnished" and not "filed," which affects legal incorporation and Section 18 liability. Until Exhibit 99.1 is reviewed, the filing should be treated as a formal notice rather than a source of metrics.
TL;DR: Compliance appears standard 鈥� results furnished and XBRL provided; lack of embedded figures reduces immediate materiality.
The company attached the press release as Exhibit 99.1 and an Inline XBRL interactive data file as Exhibit 104, indicating efforts to provide machine-readable disclosures. The explicit statement that the information is "furnished" rather than "filed" is a common legal distinction that limits incorporation into other filings. From a governance and disclosure-process view, the 8-K meets routine disclosure requirements, but it is not materially informative by itself without the contents of the press release.
Y-mAbs Therapeutics ha comunicato di aver reso noti i risultati finanziari per il trimestre terminato il 30 giugno 2025 e ha allegato il comunicato stampa come Exhibit 99.1 a questo Form 8-K. Il deposito precisa che il materiale fornito, incluso l'Exhibit 99.1, non deve essere considerato "filed" ai fini della Section 18 of the Exchange Act e non 猫 incorporato per riferimento in altre dichiarazioni, salvo esplicito riferimento.
Il testo di questo 8-K non contiene metriche finanziarie n茅 risultati operativi; un Interactive Data File (Inline XBRL) 猫 incluso come Exhibit 104. Gli investitori devono consultare il comunicato stampa allegato per i dettagli finanziari completi.
Y-mAbs Therapeutics inform贸 que ha anunciado sus resultados financieros del trimestre terminado el 30 de junio de 2025 y ha presentado el comunicado de prensa como Exhibit 99.1 en este Form 8-K. El documento indica que el material suministrado, incluido el Exhibit 99.1, no debe considerarse "filed" a efectos de la Section 18 of the Exchange Act y no se incorpora por referencia en otros formularios salvo que se haga referencia expl铆cita.
El texto de este 8-K no incluye m茅tricas financieras ni resultados operativos; un Interactive Data File (Inline XBRL) figura como Exhibit 104. Los inversores deben revisar el comunicado de prensa adjunto para conocer los detalles financieros.
Y-mAbs Therapeutics電� 2025雲� 6鞗� 30鞚�搿� 雭濍倶電� 攵勱赴鞚� 鞛鞁れ爜鞚� 氚滍憸頄堨溂氅�, 甏�霠� 氤措弰鞛愲毳� 鞚� Form 8-K鞚� Exhibit 99.1搿� 鞝滌稖頄堧嫟瓿� 氚濏様鞀惦媹雼�. 鞝滌稖靹滊電� 鞝滉车霅� 鞛愲(頃措嫻 Exhibit 99.1 韽暔)臧赌 Section 18 of the Exchange Act鞚� 氇╈爜靸� "filed"搿� 臧勳＜霅橃 鞎婌溂氅�, 氇呾嫓鞝� 彀胳“臧� 鞛堧姅 瓴届毎毳� 鞝滌櫢頃橁碃 雼るジ 鞝滌稖靹滊鞐� 彀胳“搿� 韽暔霅橃 鞎婋姅雼り碃 氇呾嫓頃╇媹雼�.
鞚� 8-K鞚� 氤鸽鞐愲姅 鞛 歆�響滊倶 鞓侅梾鞁れ爜鞚� 韽暔霅橃柎 鞛堨 鞎婌溂氅�, Interactive Data File (Inline XBRL)鞚� Exhibit 104搿� 觳秬霅橃柎 鞛堨姷雼堧嫟. 鞁れ牅 鞛 靹鸽秬靷暛鞚� 觳秬霅� 氤措弰鞛愲毳� 頇曥澑頃挫暭 頃╇媹雼�.
Y-mAbs Therapeutics a annonc茅 avoir publi茅 ses r茅sultats financiers pour le trimestre clos le 30 juin 2025 et avoir communiqu茅 le communiqu茅 de presse correspondant en tant que Exhibit 99.1 de ce Form 8-K. Le d茅p么t pr茅cise que les documents fournis, y compris l'Exhibit 99.1, ne doivent pas 锚tre consid茅r茅s comme "filed" aux fins de la Section 18 of the Exchange Act et ne sont pas incorpor茅s par r茅f茅rence dans d'autres d茅p么ts sauf mention expresse.
Le texte de ce 8-K ne contient aucune donn茅e financi猫re ni r茅sultat op茅rationnel ; un Interactive Data File (Inline XBRL) est joint en tant que Exhibit 104. Les investisseurs doivent consulter le communiqu茅 de presse ci-joint pour obtenir les d茅tails financiers.
Y-mAbs Therapeutics teilte mit, dass das Unternehmen seine Finanzergebnisse f眉r das Quartal zum 30. Juni 2025 bekanntgegeben und die zugeh枚rige Pressemitteilung als Exhibit 99.1 zu diesem Form 8-K eingereicht hat. Die Einreichung weist darauf hin, dass das bereitgestellte Material, einschlie脽lich des Exhibit 99.1, im Sinne von Section 18 of the Exchange Act nicht als "filed" gilt und nicht durch Verweis in andere Unterlagen aufgenommen wird, es sei denn, dies geschieht ausdr眉cklich.
Der Text dieses 8-K enth盲lt keine finanziellen Kennzahlen oder Betriebsergebnisse; eine Interactive Data File (Inline XBRL) ist als Exhibit 104 beigef眉gt. Anleger m眉ssen die beigef眉gte Pressemitteilung einsehen, um die konkreten Finanzangaben zu erhalten.
FAQ
What did Y-mAbs (YMAB) announce in this 8-K?
Does the 8-K include financial numbers for YMAB's quarter?
Is the press release considered "filed" with the SEC?
Is machine-readable data provided?
Where can I find the actual financial details mentioned?
